Riociguat (Adempas, BAY63-2521) clinical trials

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

This study looks at a medicine called riociguat (Adempas) for children aged 6 to 17 with pulmonary arterial hypertension (PAH). The aim is to check if it's safe and works well at different doses to help manage this lung condition.